A phase i trial of PD 0332991, a novel, orally-bioavailable CDK4/6-specific inhibitor administered in combination with bortezomib and dexamethasone to patients with relapsed and refractory multiple myeloma

This article has no abstract
Epistemonikos ID: 70b68908844d48aaba0e2ba8fac8a17d78c702ea
First added on: Mar 01, 2025